Mycophenolate Mofetil-d4
(Synonyms: 吗替麦考酚酯 d4) 目录号 : GC47712
An internal standard for the quantification of mycophenolate mofetil
Cas No.:1132748-21-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Mycophenolate mofetil-d4 is intended for use as an internal standard for the quantification of mycophenolate mofetil by GC- or LC-MS. Mycophenolate mofetil is a prodrug form of mycophenolic acid .1,2,3 In vivo, mycophenolate mofetil (12.5 mg/kg) increases duration of transplant motor activity in a rabbit model of retroperitoneal heterotopic heart transplantation.1 It eliminates formation of microbleeds and hemorrhages in the cerebrum of stroke-prone spontaneously hypertensive rats.2 Mycophenolate mofetil also lowers mean arterial pressure (MAP) and reduces urinary albumin excretion and glomerulosclerosis, markers of renal damage, in a mouse model of systemic lupus erythematosus (SLE).3
1.AygÜn, F., Efe, D., and Durgut, K.Comparison of MMF with prednisone in terms of rejection and duration of activity of transplant in rabbits that underwent retroperitoneal heterotopic heart transplantationCardiovasc. J. Afr.26(3)104-108(2015) 2.Dhande, I.S., Zhu, Y., Braun, M.C., et al.Mycophenolate mofetil prevents cerebrovascular injury in stroke-prone spontaneously hypertensive ratsPhysiol. Genomics49(3)132-140(2017) 3.Taylor, E.B., and Ryan, M.J.Immunosuppression with mycophenolate mofetil attenuates hypertension in an experimental model of autoimmune diseaseJ. Am. Heart Assoc.6(3)e005394(2017)
| Cas No. | 1132748-21-0 | SDF | |
| 别名 | 吗替麦考酚酯 d4 | ||
| Canonical SMILES | O=C(OC1)C2=C1C(C)=C(OC)C(C/C=C(C)/CCC(OC([2H])([2H])C([2H])([2H])N3CCOCC3)=O)=C2O | ||
| 分子式 | C23H27D4NO7 | 分子量 | 437.5 |
| 溶解度 | DMF: 14 mg/ml,DMSO: 10 mg/ml,Ethanol: 1.4 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2857 mL | 11.4286 mL | 22.8571 mL |
| 5 mM | 0.4571 mL | 2.2857 mL | 4.5714 mL |
| 10 mM | 0.2286 mL | 1.1429 mL | 2.2857 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Liquid chromatography tandem mass spectrometry method for the quantitation of mycophenolate mofetil in human plasma: Application to a bioequivalence study and metabolite identification
J Sep Sci 2015 Oct;38(20):3533-44.PMID:26383052DOI:10.1002/jssc.201500779
We established a sensitive, selective, and rapid analytical method for the quantitation and pharmacokinetic investigation of mycophenolate mofetil in human plasma. To our knowledge, this is the first method that characterizes presence of mycophenolate mofetil glucuronide in clinical samples through tandem mass spectrometry detection and resolves mycophenolate mofetil from its glucuronide metabolite. Liquid chromatography coupled to tandem mass spectrometry detection in positive ion mode was selected to provide optimal selectivity and sensitivity. Due to the ionizable characteristics of the mycophenolate mofetil, a mixed-mode cation-exchange disposable extraction cartridge was prudently chosen. The chromatographic separation was achieved on Luna(®) C18(2) (100×4.60 mm) column using mobile phase consisting of a mixture of 1±0.05 mM ammonium formate in water, titrated to pH 3.1±0.1 with formic acid, and methanol (20:80, v/v), at a flow rate of 0.7 mL/min. The detection was led at m/z ratios of 434.4→ 114.2 and 438.4→ 118.3, for mycophenolate mofetil and Mycophenolate Mofetil-d4, respectively. The developed method was linear between 40.2-4986.0 pg/mL. All validation parameters were within the defined limits. The validated method was then successfully applied for the evaluation of bioequivalence parameters of mycophenolate mofetil after an oral administration of 500 mg mycophenolate mofetil tablet to healthy male Indian volunteers.